Encouraging results from combination therapy in Hodgkin lymphoma

The research team evaluated the combination of the biologic therapy brentuximab vedotin (Adcetris), a monoclonal antibody-drug conjugate, with the chemotherapy drug gemcitabine (Gemzar) in 42 pediatric and young-adult patients with Hodgkin lymphoma, the most common cancer in young people ages 15 to 29.

The researchers report that these two therapies together represent a highly active combination for refractory or relapsed Hodgkin lymphoma, with a complete response rate exceeding that seen with standard therapy or following administration of either brentuximab vedotin or gemcitabine alone. Among the evaluable patients in the newly reported phase II study, 23 (58%) achieved complete response to the combination within four cycles, and 6 (15%) had a partial response.

"We found very high response rates to this treatment combination, which has the added benefit of having a much reduced risk of long-term organ damage compared to the highly toxic chemotherapy agents typically used for patients with relapsed Hodgkin lymphoma," says Dr. Kelly, who is Program Director of the Pediatric Hematology/Oncology Service Line at the Women & Children's Hospital of Buffalo and holds an additional faculty appointment with the University at Buffalo. "We're encouraged at the prospect that these findings, if confirmed in a phase III study, might represent a new standard of care for one of our most common pediatric and young-adult cancers."